AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia

This study has been completed.

Sponsor:

Information provided by:

National Institutes of Health Clinical Center (CC)

ClinicalTrials.gov Identifier:

NCT00321581

First received: May 3, 2006

Last updated: May 3, 2013

Last verified: June 2012

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	October 2011
Estimated Primary Completion Date:	No date given

No publications provided by National Institutes of Health Clinical Center (CC)

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Fox E, Aplenc R, Bagatell R, Chuk MK, Dombi E, Goodspeed W, Goodwin A, Kromplewski M, Jayaprakash N, Marotti M, Brown KH, Wenrich B, Adamson PC, Widemann BC, Balis FM. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol. 2010 Dec 10;28(35):5174-81. Epub 2010 Nov 8.

To Top